Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 5,532,159 shares, an increase of 32.2% from the December 15th total of 4,184,652 shares. Based on an average trading volume of 1,911,674 shares, the days-to-cover ratio is currently 2.9 days. Currently, 4.2% of the shares of the company are short sold. Currently, 4.2% of the shares of the company are short sold. Based on an average trading volume of 1,911,674 shares, the days-to-cover ratio is currently 2.9 days.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ALNY. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Truist Financial reduced their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Oppenheimer initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. Finally, Bank of America cut their target price on Alnylam Pharmaceuticals from $530.00 to $529.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. Twenty-two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $490.96.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,650 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,675,409.21. The trade was a 19.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,780 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 56,955 shares of company stock worth $24,072,733. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $29,000. Atlantic Union Bankshares Corp purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $30,000. Finally, Ameriflex Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $32,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $359.27 on Tuesday. The business’s fifty day simple moving average is $417.09 and its 200-day simple moving average is $422.89. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a market cap of $47.46 billion, a PE ratio of 1,496.96 and a beta of 0.32.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.